Michael Hanna Vaccinogen cancer vaccine prostate cancer

The Problem with Cancer Vaccines

  You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeaway message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tumour cell vaccine OncoVAX, to discuss why there have been so many high-profile cancer vaccine failures and how this has affected …

Liver Cancer Vaccine Effective In Mice

Antigen Engineering has allowed scientists to formulate a cancer vaccine that is effective in preventing liver cancer in mice. By modifying Alpha-Fetoprotien (AFP), an antigen for liver cancer, Dr. Yukai He was able to make it so that the immune system would still recognise it, but would keep the protein expressed by cancer cells. AFP is expressed during development and …

Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute

Research program will use Intensity’s in situ chemovaccination technology May 28, 2014 Intensity Therapeutics, Inc. (private) announced today that the Company established a cooperative research and development agreement (CRADA), with the National Institute of Health’s National Cancer Institute (NCI) Vaccine Branch. Intensity Therapeutics was awarded the CRADA by the NCI to study the efficacy and mechanism of action of Intensity’s in situchemovaccination products using in …

Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating its Immunotherapy Candidate CV-301 in Bladder Cancer

April 28, 2014 Bavarian Nordic A/S announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer. In the study, sponsored by the National Cancer Institute, 54 patients with high grade non-muscle invasive bladder cancer whose cancer has progressed after initial BCG (Bacillus Calmette-Guerin) treatment will …